News
Co-Founder Dominik Witzigmann on Willing to Win: “The fight for thousands is not over”
WILLING TO WIN ⋅ EPISODE 17
The fight for thousands is not over.
Dr. Dominik Witzigmann, Co-Founder and President, in conversation with Christian Rados
Our co-founder Dominik Witzigmann sat down with Christian Rados, founder of Rados Recruiting and host of the biotech leadership podcast Willing to Win, to talk about what the hardest moment in his life did to the way he builds NanoVation: how we treat people, the leadership and hiring principles that keep the team aligned with the vision, and why the patient is the North Star. In his words.
“My daughter Lotta passed away close to the age of four because of leukemia. Eight weeks from the first pain in her arms and legs to the end. You can grieve, and you go on grieving, but how can you transform that moment? I will never get my daughter back, but I can help others. I can have an impact on the people in the team, and on patients, with NanoVation and the partners we work with.”
Family first, above everything
I was open and told the team what happened. One of our board members immediately wrote me: “Family first, above everything.” This is what I have told my team since, whenever someone loses a loved one. Family first, above everything. Your team will deal with it. Take time. We will handle it. We are one team. TEAM: Together Everyone Achieves More.
Our friends put a lasagna in front of the door and texted: there is food in front of your home. In that situation you need help, but you don’t have time to think about what you need. “Call me if you need anything” means nobody will call.
Team members who will work with that person are part of the final stage. If four of five say it doesn’t click, we will not hire that person, because in the end they have to work together. And if there is friction, be honest: changing personalities is almost impossible. Sometimes you have to let someone go. Anyone who left NanoVation, I try to keep a good relationship and help them find new jobs.
Having seen my child in a devastating situation brings everything into perspective. The world will not break apart if I don’t solve this within the next hour. Then I focus on the problem. This is what we tell the team: if there is a problem, come with solutions.
Impact
Impact is patients. That is the North Star I always follow. If we solve a delivery problem, the team will be motivated, the shareholders will profit, and so will the partners who drive the therapy into the clinic. Keep focused on that North Star and everything else comes with it.
Meet patients
A scientist thinks about the assays, the studies, the work plan. A patient thinks about the next birthday, the next day when they feel better. I have asked families whether I may share the story of their child with my team. It changes so much.
Where LNPs matter next
Cancer vaccines, in vivo CAR-T, autoimmune disease. Ugur Sahin said that by the mid-2030s one third of all drugs will be genetic medicines. We know the origin of many diseases now, not only the symptoms, and we can correct it. What you always need is the delivery solution.
Starting a company
Take opportunities when they are there. When the doors are open, be ready to say yes and step through. I would never start a company alone. And go into it like a marriage: you don’t start with the question of when you exit.
A letter from my 80-year-old self
Stay focused on an impact that goes beyond the 80 years. I want to do something that makes the world a slightly better place and outlasts my time. The best way to predict the future is to create it yourself.
Watch or listen to the full conversation
Watch on YouTube Listen on Spotify
Prefer to read? The full conversation, lightly edited, is on the Rados Recruiting website.
About NanoVation Therapeutics
NanoVation Therapeutics is a Vancouver-based biotechnology company developing long-circulating lipid nanoparticle (lcLNP™) technology for genetic medicines. Founded on proprietary lipid chemistry and LNP engineering expertise, NanoVation’s platform enables functional delivery to extrahepatic tissues including immune cells, bone marrow, and tumors, without the need for targeting ligands. The company partners with pharmaceutical and biotech organizations to advance xRNA, DNA, and gene editing programs that require delivery beyond the liver.